Faron Pharmaceuticals Oy
FARN · AIM · Health Care · mcap £77m · 36.5p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 06 Oct 26 | Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board
(AIM: FARN, First North: FARON), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient’s own immune system, today announces that the following membe |
+0.0% | |
| 30 Sep 26 | Convertible bond amortization payment deferred by mutual agreement with HCM
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company and Heights Capital Management, Inc. |
−3.9% | |
| 17 Sep 26 | Issuance of warrants
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company, announces that it has issued to IPF Fund II SCA, SICAV-FIAR (“IPF”) 153,917 additional warrants over ordinary shares in the Company (“Warrants” |
+0.0% | |
| 26 Aug 26 | Results | Half-year Results
Strengthened balance sheet supports advancement into randomized Phase 2b trial in higher-risk MDS |
−2.4% |
| 19 Aug 26 | Notice of Half-Year Financial Results
Faron Pharmaceuticals will publish its half-year financial results for January-June 2026 on Wednesday 26 August 2026 |
+4.7% | |
| 03 Aug 26 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 3,657,321 special rights entitling to 3,657,321 shares |
+0.0% |
| 27 Jul 26 | Inside Information: Faron announces encouraging first overall survival data from frontline higher-risk (HR) MDS patients in the BEXMAB phase 1/2 trial
Inside Information: After a median follow-up of 14.9 months, median overall survival has not yet been reached in frontline HR MDS without TP53 mutations, nor has it yet been reached for monoallelic TP53 mutated patients. |
+2.5% | |
| 11 Jun 26 | Registration of Treasury Shares
Capitalised terms used in this announcement have the meanings given to them in the announcement made on 28 May 2026 at 15:35 EEST regarding the issue of treasury shares to the Company, unless the context provides otherwi |
+0.0% | |
| 05 Jun 26 | Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee
The Disciplinary Committee dismissed two of the alleged breaches claimed by the market surveillance, importantly, an allegation that the Company’s administration was not organized in a manner required of a listed company |
−3.0% | |
| 03 Jun 26 | Registration of New Shares
Capitalised terms used in this announcement have the meanings given to them in the announcement made on 3 June 2026 at 09:00 EEST regarding the amortisation payment and approval of share subscriptions based on special ri |
+0.0% | |
| 03 Jun 26 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 3,366,377 special rights entitling to 3,366,377 new Sh |
+0.0% |
| 28 May 26 | Issue of Treasury Shares to the Company
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the Board of Directors of Faron (the “Board”) has resolved to issue 21,469 |
+1.1% | |
| 28 May 26 | Special Rights attached to the First and Second Tranche of Bonds
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the Board has resolved, based on the authorisation granted by the General |
+1.1% | |
| 06 May 26 | Termination of Liquidity Provision Service
Faron has terminated the liquidity providing agreement with Lago Kapital |
−4.5% | |
| 05 May 26 | Directorate Appointment
(“Faron”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies, is pleased to announce the appointment of Dr. |
+6.0% | |
| 04 May 26 | Result of AGM
Faron Pharmaceuticals Ltd: Results of the Annual General Meeting |
+6.0% | |
| 30 Apr 26 | Issuance of warrants
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company, announces that it has issued to IPF Fund II SCA, SICAV-FIAR (“IPF”) 321,523 additional warrants over ordinary shares in the Company (“Warrants” |
+7.2% | |
| 14 Apr 26 | Remaining offer shares registered with Finnish Trade Register
Faron Pharmaceuticals Ltd: Remaining offer shares registered with Finnish Trade Register |
−2.2% | |
| 14 Apr 26 | Registration of New Shares
Capitalised terms used in this announcement have the meanings given to them in the announcement made on 13 April 2026 at 14:00. |
−2.2% | |
| 13 Apr 26 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 3,572,851 special rights entitling to 3,572,851 new Sh |
+4.4% |
| 10 Apr 26 | Notice Of Faron Pharmaceuticals Ltd’s Annual General Meeting
Shareholders of Faron Pharmaceuticals Ltd (the “Company”) are notified of the Annual General Meeting (the “AGM”) to be held on 4 May 2026 at 10:00 a.m. |
−11.2% | |
| 10 Apr 26 | New shares registered with Finnish Trade Register
Faron Pharmaceuticals Ltd: New shares registered with Finnish Trade Register |
−11.2% | |
| 09 Apr 26 | Results | Faron publishes final results of its EUR 40.1 million rights issue
Faron publishes final results of its EUR 40.1 million rights issue |
−8.4% |
| 08 Apr 26 | Results | Inside Information: Faron publishes preliminary results of its successful rights issue
Inside Information: Faron publishes preliminary results of its successful rights issue |
+4.9% |
| 30 Mar 26 | Suspension - Faron Pharmaceuticals Oy | +1.1% | |
| 26 Mar 26 | Faron appoints new CTO to strengthen late-stage development activities
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company, announces the appointment of Mr. |
+1.2% | |
| 11 Mar 26 | The Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus
(AIM: FARN, First North: FARON, “Faron” or the “Company”) announced through a company announcement on 10 March 2026 a resolution by the Company’s Board of Directors on a fully committed rights offering of approximately E |
−4.5% | |
| 10 Mar 26 | Inside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway
Inside Information: Faron publishes terms and conditions for approximately EUR 40m rights offering fully-covered from combination of cornerstone investments, subscription commitments, and guarantees and updates cash runw |
+4.9% | |
| 09 Mar 26 | Update to Faron’s Financial Calendar and date of the Annual General Meeting in 2026
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces an update for the Company’s financial calendar 2026. |
−4.7% | |
| 04 Mar 26 | Results | Faron Pharmaceuticals Ltd’s Annual Report 2025 published
(AIM: FARN, First North: FARON), announces a correction to the company announcement of its Annual Report 2025, originally published on 4 March 2026 at 09:15 EET. |
+13.7% |
| 04 Mar 26 | Results | Faron Pharmaceuticals Ltd’s Annual Report 2025 published
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today published the Annual Report for 2025. |
+13.7% |
| 04 Mar 26 | Faron’s Financial Statements Release 1 January to 31 December 2025
Continued steady progress with bexmarilimab and solidifying position as a leading macrophage based immunotherapy under development |
+13.7% | |
| 02 Mar 26 | Result of General Meeting
TURKU - FINLAND 2 March 2026 – Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the extraordinary |
−6.1% | |
| 09 Feb 26 | Notice To The Extraordinary General Meeting
Shareholders of Faron Pharmaceuticals Ltd (business ID: 2068285-4, the “Company”) are notified of the Extraordinary General Meeting (the “EGM”) to be held on 2 March 2026 at 10:00 a.m. |
−1.5% | |
| 09 Feb 26 | Inside Information: Faron Pharmaceuticals Ltd is planning a rights offering of approximately EUR 40 million to strengthen its capital structure and to drive lead asset bexmarilimab to key milestones
Inside Information: Faron Pharmaceuticals Ltd is planning a rights offering of approximately EUR 40 million to strengthen its capital structure and to drive lead asset bexmarilimab to key milestones |
−1.5% | |
| 03 Feb 26 | Registration of New Shares
Capitalised terms used in this announcement have the meanings given to them in the announcement made at 9.00 a.m. |
−1.5% | |
| 03 Feb 26 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 909,517 special rights entitling to 909,517 new Shares |
−1.5% |
| 08 Jan 26 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 453,979 special rights entitling to 453,979 existing t |
+4.0% |
| 17 Dec 25 | Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the following members have been re-elected by a meeting of the Compa |
+0.0% | |
| 11 Dec 25 | Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement
(AIM: FARN, First North: FARON, “Faron” or the “Company”), a clinical-stage biopharmaceutical company developing novel immunotherapies, announced on 3 April 2025 that the Company has entered into a subscription agreement |
+0.0% | |
| 03 Dec 25 | Registration of New Shares
Capitalised terms used in this announcement have the meanings given to them in the announcement made at 9.00 a.m. |
+0.0% | |
| 03 Dec 25 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 517,795 special rights entitling to 517,795 new Shares |
+0.0% |
| 01 Dec 25 | Board change | Appointment of CFO
Faron appoints new CFO to support next phase of growth |
+0.0% |
| 27 Nov 25 | Faron’s Financial Calendar for 2026
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the following dates for the Company’s financial reporting in 2026: |
+4.1% | |
| 24 Nov 25 | INSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT
Inside Information: Faron intends to issue second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement |
+0.0% | |
| 28 Oct 25 | Fundraise | Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds
(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 451,803 special rights entitling to 451,803 new Shares |
−1.3% |
| 20 Oct 25 | Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients
Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients with an 85% ORR and a 45% CR rate, bolstered by pharm |
+1.4% |
Company filings. Not investment advice.